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ABSTRACT
Alternative splicing is widespread in the human
genome, and it appears that many genes display
different splice forms in cancerous tissue than in
normal human tissues. However, since cDNAs for
many cancer-associated genes were originally
cloned from tumor samples, it is important to ask
whetherthisrepertoireofcDNAsprovidesacomplete
or representative picture of the transcript isoforms
found in normal tissues. To answer this, we used
bioinformatics and RT–PCR to identify novel splice
forms, focusing on in-frame exonskips, for a panel
of 50 cancer-associated genes in normal tissue
samples. These data show that in nearly two-thirds
of the genes, normal tissues expressed previously
unknown splice forms, of which 40% were normally
a dominant splice form. Surprisingly, the tumor-
associated splice forms were twice as likely to be
represented in GenBank than their normal tissue-
associated splice forms, most likely because 70% of
the mRNAs in GenBank for these genes were cloned
from tumor samples. As an example, we describe a
novel normal splice form of IKBb, an important
regulator of the NFkB pathway. Our data suggest
that systematic re-evaluation of cancer genes’ splice
forms in normal tissue will yield insights into their
distinct functions in normal tissues and in cancer.
Our database contains 1308 novel normal splice
forms, including many known cancer genes.
INTRODUCTION
Comprehensive and accurate mRNA sequence data are
essential for the study of gene function. Researchers rely on
sequence data from public databases and large-scale sequen-
cing projects. For example, cancer researchers have sought
to identify genes that are differentially expressed in tumors
versus normal tissues (1,2), often using techniques such as
PCR and microarrays where good probe design relies on
existing mRNA sequence information.
Recent studies, however, have indicated that the mRNA
sequences in current databases may reﬂect only a small pro-
portion of all transcripts in the human genome. The unexpec-
tedly low number of predicted genes in the completed human
genome has led researchers to new questions about genome
complexity. In particular, genomics studies have recently
shown that most genes in the human genome are alternatively
spliced to produce multiple mRNA products, most of which
were previously unknown [reviewed in (3–5)]. A wide variety
of experimental approaches including high-throughput
expressed sequence tag (EST) sequencing (6), full-length
cDNA sequencing (7,8), microarrays (9) and other methods
(10) indicate that 40–60% of human genes are alternatively
spliced. For example, an analysis of human EST and genome
sequence data from January 2002 detected more than 30000
alternative splices in the human genome, effectively doubling
the number of gene products expected from the estimated
32000 human genes (11).
These new sources of genomic complexity pose a signif-
icant challenge and opportunity to biological researchers.
On the one hand, these data indicate that public databases
may be missing a very large fraction of human gene products.
The majority of alternative splice forms identiﬁed from
EST sequencing were novel (12), i.e. they were not found
in any mRNA sequence deposited in GenBank, or in any
protein sequence record in SwissProt. Since these isoforms
are not represented in public databases, and often cause subtle
effects on the protein product (e.g. removal of only a small
segment of the protein), they form a worrisome blindspot
in biological research. Fortunately, new data from genomics
and bioinformatics are rapidly closing this gap by providing
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Cancer research is one area where these alternative splicing
data may provide a useful new perspective. Recently, there has
been growing evidence for the importance of tumor-speciﬁc
splice variants in cancer, both from bioinformatics studies of
expressed sequence databases and from experimental studies
(13–18). For example, Bin1, one of the genes identiﬁed by our
bioinformatics analysis as displaying cancer-speciﬁc splicing
(14), is an adapter protein with features of a tumor suppressor
that binds to and inhibits the oncogenic properties of c-Myc
(19). Its expression is lost in many tumors. (20,21). Previous
studies by Prendergast and co-workers (22) have shown that
Bin1 function is abrogated in melanoma cells by aberrant
splicing ofa tissue-speciﬁc exon. Speciﬁcally, mostmelanoma
cells inappropriately expressed exon 12A, which is combined
with other alternative exons in Bin1 isoforms in brain, but is
not found in isoforms from melanocytes or other non-neuronal
cells. Cotransfection experiments in rat ﬁbroblasts showed
that exon 12A abolishes the ability of Bin1 to inhibit
malignant transformation by c-Myc or adenovirus E1A. Splice
variants may also be used as diagnostic markers for cancer
(16). For example, a novel splice variant of actinin-4 is
speciﬁc to SCLC (small cell lung carcinoma) cell lines,
suggesting that it may be used as a new diagnostic marker
for this disease (23).
Shifting from a paradigm of ‘one gene, one protein’ to
recognition of widespread alternative splicing raises an
important question for studies of disease genes, such as
cancer-associated genes. Under the ‘one gene, one protein’
model, a cancer gene is assumed to produce the same protein
product in tumors as in normal tissues, and its role in cancer is
attributed to changes in the regulation of its expression, etc.
However, if a typical gene can have multiple splice forms, we
also need to ask whether there might be changes in splicing
between the protein product found in normal tissues versus
the form found in tumors. For disease genes, such as genes
identiﬁed in association with cancer, this raises a speciﬁc
concern. If such a gene were cloned originally from a
tumor cDNA library, how can we be sure that this mRNA
sequence is truly the splice form found in normal tissue, and
not a tumor-speciﬁc splice variant? Since many genes studied
by cancer researchers were indeed originally cloned from
tumors, this concern warrants further examination.
In this study we have sought to evaluate this question
directly, by examining the alternative splicing patterns of
50 genes in normal human tissue samples. We focused on a
panel of 50 genes with cancer-associated alternative splicing,
i.e. signiﬁcant shifts in alternative splicing frequencies
between tumors versus normal samples. We also focused
our study on in-frame exon skips (i.e. alternative splicing
events that add or remove an exact multiple of 3 nt, leaving
the protein reading frame unchanged), to avoid including
alternative splice forms that might cause nonsense-mediated
decay (24). Using a combination of bioinformatics analysis
and RT–PCR, we identiﬁed novel splice forms and evaluated
their prevalence in normal tissue samples. These data show
that nearly two-thirds of the genes expressed novel, previously
unknown splice forms in normal human tissue samples, and
indicate that in 40% of the cases the novel splice form was the
dominant splice form in normal tissues.
MATERIALS AND METHODS
Genome-wide detection of cancer-specific
alternative splicing
We based our analysis on our previously validated identiﬁca-
tion of alternative splicing from human ESTs aligned to
genomic sequence (11,12). Cancer-speciﬁc splicing was
detected as described previously in (14). Brieﬂy, to identify
changes in splicing that are characteristic of the transformed
state, we pooled 4067 EST libraries from tumor samples and
compared against a separate pool of 1737 EST libraries from
normal tissue. By pooling many different tumors, we sought
speciﬁc characteristics that are shared by many cancer types,
and which are present far more frequently in tumors than in
normal samples. We used histological information provided
by ORESTES (Ludwig Institute for Cancer Research, http://
www.ludwig.org.br/ORESTES), NCI-CGAP (Cancer Genome
Anatomy Project, http://cgap.nci.nih.gov/) and NIH-MGC
(Mammalian Gene Collection, http://mgc.nci.nih.gov/). We
also performed text searches to classify other EST libraries.
All tumor types were combined into a single pool, as were all
normal tissue libraries. A total of 1160 EST libraries were
excluded because they could not be clearly assigned to either
cancer or normal (for example, if its histology was unclear
or pre-cancerous). To assess the statistical signiﬁcance based
on EST coverage, we assigned an LOD score to each pair of
splices, giving the log-odds ratio for a statistically signiﬁcant
change in the ratio of the two splice forms, as described in
detail in (14). By this LOD score measure, we detected cancer-
speciﬁc alternative splicing in 1284 genes at low conﬁdence
(P-value < 0.05) and 316 genes at high conﬁdence (LOD
score 2 or greater, i.e. P < 0.01), with 89 genes above LOD 3
(P < 0.001). A splice was considered novel, if there were
no complete mRNAs deposited in GenBank matching this
splice event. For this study, we focused on novel splices
that were detected in normal tissues, referred to as ‘novel
normals’. For experimental validation, we selected a random
sample of ‘novel normal’ splices that are in-frame exon skips,
i.e. which add or remove an exact multiple of 3 nt, causing
no change to the protein reading frame. We used this criterion
to avoid alternative splicing events that might cause frame
shifts in protein coding regions and thus introduce premature
stop codons, possibly resulting in nonsense-mediated decay
of the transcript (24).
To measure the representation of our normal-speciﬁc versus
cancer-speciﬁc splice forms inhuman mRNAs from GenBank,
we downloaded the human UniGene dataset for February 2005
and selected all sequences of type mRNA. For each splice
being tested, we concatenated the nucleotide sequences of
the two exons joined by that splice (including up to 100 nt
of sequence adjoining the splice from each exon) and searched
the mRNA database using BLAST and an expectation value
cutoff of 0.001. Any hit of at least 99% identity to the probe
sequence was treated as a match to that speciﬁc splice form.
Cell lines
Cell lines used were SKNSH, SKNMC and U87 from ATCC
(www.atcc.org); F-508 and W-98 (25,26) were kindly pro-
vided by Dr Linda Liau and Dr Stan Nelson (UCLA, Los
Angeles, CA). SKNSH and SKNMC are neuroblastoma cell
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cell lines were grown in RPMI 1640 medium supplemented
with L-glutamine, 10% fetal calf serum, 100 U/ml penicillin
and 100 U/ml streptomycin at 5% CO2.
RNA preparation
Total RNA was isolated from cell lines by using the
Absolutely RNA microprep kit (Stratagene, La Jolla, CA).
To remove genomic DNA contamination, DNase treatment
was performed as recommended by the kit manufacturers.
Total RNA from normal human bone marrow, brain, breast,
skeletal muscle, lung, placenta and testis were purchased from
BD-Biosciences Clontech (Palo Alto, CA).
cDNA synthesis and RT–PCR
cDNA was synthesized using either oligo(dT)12–18 or random
hexamers and Stratascript reverse transcriptase using the
StrataScript First-Strand Synthesis System (Stratagene).
cDNAs from both reactions were pooled before performing
PCR. This was performed to increase coverage of the
entire gene.
Gene-speciﬁc primers were designed using MIT Primer3
software and synthesized by MWG Biotech (High Point,
NC). All primers ﬂanked at least one exon–intron junction
(to rule out artefacts from genomic DNA contamination)
and all had Tm between 55 and 60 C. Primer sequences are
available online. GAPDH levels were monitored as a control.
Touchdown PCR was performed on the MJR PTC-0200 ther-
mal cycler (MJ Research, South San Francisco, CA) using Taq
polymerase (Qiagen, Valencia, CA). Touchdown PCR condi-
tions were as follows: 95 C for 2 min; 10· (95 C for 1 min;
65 C for 1 min with a decrease of 1 C per cycle; 72 C for 1
min), 30· (95 C for 1 min; 55 C for 1 min; 72 C for 1 min);
72 C for 10 min; hold at 4 C. Reaction products were run on a
2–2.5% agarose gel and visualized by staining with Ethidium
Bromide (Sigma–Aldrich, St Louis, MO). As an internal con-
trol for successful PCR, we required that at least one band,
corresponding to the known splice form was observed. PCR
products were gel puriﬁed using a Qiaquick gel puriﬁcation
kit (Qiagen). Gel puriﬁed products were sequenced in both
directions using gene-speciﬁc primers and Amersham
MegaBACE 1000 sequencers (Amersham Pharmacia Biotech,
Piscataway, NJ). The results conﬁrmed the expected DNA
sequences in all cases.
RESULTS
Screening of ‘novel normal’ splice forms of
50 genes in normal tissue samples
Usingasetofgeneswithcancer-associatedshifts inalternative
splicing (14), we searched for novel splice forms via a bioin-
formatics analysis of human ESTs. A splice form was deﬁned
as novel if it was not observed in any complete mRNA depos-
itedinGenBank(seeMaterialsandMethods).Inparticular,we
focused on novel splices that were detected in ESTs derived
from normal tissues, which we will refer to as ‘novel normal’
splice forms, since they appeared to be novel splice forms
expressed in normal tissues. We detected a total of 1308
‘novel normal’ splices (with LOD scores of >1.0) in 804
genes, of which 472 were exon skip events.
To assess the validity of these novel normal splices, we
selected a random sample of 50 single-exon skip events and
used RT–PCR to detect both the proposed novel splice form
and the known splice form, i.e. that reported in GenBank. We
designed primer pairs directed to the exons ﬂanking the altern-
ativelysplicedexon,so thata single primerpair would amplify
both the known and novel splice forms, yielding different PCR
product sizes. Thus, all our primer pairs spanned at least two
introns. This probe design rules out artifacts due to genomic
contamination or incomplete mRNA processing, since the
transcript must be correctly spliced to yield the expected prod-
uct sizes for the known and novel splice forms. We selected
one or more normal tissues to test for each gene, based on the
tissue origin of the ESTs in which the novel splice form was
reported by our bioinformatics study.
A total of 32 of the 50 novel splice forms (64%) were
detected by RT–PCR at the expected molecular weight
(Table 1). In all but two of these cases (DCTN1 and LEF1,
detailed in Table 1), the known splice form was also detected
at its expected molecular weight. In about one-third of the
genes (10/32), the novel splice form was detected as the dom-
inant isoform in the tissues sampled. Finally, in 18 cases we
did not detect the novel splice form, but since we only
screened two tissue samples on average in these cases, it is
possible that the novel splice form would be detected in other
normal tissues.
To ascertain the exact identity of the bands matching the
expected molecular weight of the novel splice form, we selec-
ted a random sample of 15 genes. For each gene, we gel
puriﬁed and sequenced the PCR product for the novel normal
splice form. In 15 of 15 cases tested, the independent sequen-
cing of these PCR products exactly matched the novel splice
form reported by our earlier bioinformatics study (12). Thus,
these novel splice forms are easily detected even in a small
sample of human tissues and correspond precisely to the
alternative splice forms reported by bioinformatics analysis
of ESTs.
Evaluation of literature and GenBank mRNA data
Given the ease with which these splice forms can be detected
in human tissue, it is reasonable to ask why they were not
reported by the original studies that cloned these genes, or by
subsequent entries in GenBank. To answer this question, we
ﬁrst examined the original literature to identify the tissue
sources from which these genes were originally cloned. For
a random sample of 20 genes, represented in GenBank by
44 mRNAs, 31 mRNAs (70%) were cloned from tumor sam-
ples versus 13 from normal tissue samples (see Supplementary
Data for a complete list). Thus, it is perhaps not surprising that
the GenBank records for these genes often lack the normal
splice form.
It is well known that public mRNA databases are not com-
plete in their coverage of alternative splice forms. But are they
nearing the goal of truly complete coverage? During the last
3 years, over 90000 human mRNA sequences have been
added to GenBank. We checked the latest GenBank data
(February 2005) to assess what fraction of novel normal splice
forms are now included in GenBank mRNA sequences. Of the
5028 Nucleic Acids Research, 2005, Vol. 33, No. 16novel normal splice forms identiﬁed from the January 2002
dataset, only 11% were successfully found in the February
2005 GenBank mRNA data. The remainder were not
represented by any February 2005 GenBank human mRNA,
indicating that current sequence databases are still far from
complete in their representation of human alternative splice
forms. Moreover, for this set of genes the tumor-associated
splice form was much more likely than the normal
Table 1. Validation of novel splice forms
Gene symbol Gene title Effect of novel splice Novel form detected in
ACAA1 Acetyl-CoA acyl transferase 1 N/A Not detected (BRN, LNG and TST)
BAT3
§ HLA-B associated transcript 3/human Scythe Deletion of 48 amino acids LNG and TST
BCAS1
§ Breast carcinoma amplified sequence 1 Insertion of 45 amino acids BRN
CACNA2D4 Calcium channel, voltage-dependent, a 2/d subunit 4 Deletion of 15 amino acids from
the N-terminus
BMR and SPL
CAPNS1 Calpain, small subunit 1 Deletion of 112 amino acids from
the N-terminus
BRN and TST
CCT6A Chaperonin containing TCP1, subunit 6A N/A Not detected (BRN, TST)
CCND3 Cyclin D3 N/A Not detected (BRN, LNG, TST)
CHFR
§ Checkpoint with forkhead and ring finger domains Deletion of 92 amino acids TST
COCH Coagulation factor C, cochlin Deletion of 16 amino acids TST
DARS Aspartyl-tRNA synthetase N/A Not detected (BRN)
DCTN1 Dynactin 1, p150 Insertion of seven amino acids BRN, LNG and SPL
DCTN3 Dynactin 3 (p22) N/A Not detected (PLC and SPL)
EIF4G2/p97/DAP5
§ Eukaryotic translation initiation factor 4-gamma, 2 Deletion of 38 amino acids PLC and BRST
ELN Elastin N/A Not detected (PLC, LNG and SPL)
EPB49 Erythrocyte membrane protein band 4.9 N/A Not detected (BRN)
ESRRA Estrogen-related receptor alpha N/A Not detected (BMR and SPL)
FXR1 Fragile X, mental retardation, autosomal homolog 1 N/A Not detected (SPL)
GOLGA2 Golgi autoantigen, golgin subfamily a, 2 Insertion of 27 amino acids KDN
GOSR2 Golgi SNAP receptor complex member 2 Deletion of 47 amino acids BRN, TST and PLC
HLA-DMB
§ Major histocompatibility complex, class II, DM beta Deletion of 39 amino acids BMR and PLC
ITGAE Integrin, alpha E (antigen CD103, human mucosal
lymphoyte antigen 1; alpha polypeptide)
Deletion of 32 amino acids BMR, SPL and TST
KHK Ketohexokinase Deletion of 84 amino acids BRN
LCK Lymphocyte-specific protein tyrosine kinase Deletion of 51 amino acids BMR and SPL
LEF1 Lymphoid enhancer-binding factor 1, TCF1-alpha Deletion of 28 amino acids BRN and TST
LMAN2L/VIPL Lectin, mannose-binding 2-like Insertion of 11 amino acids BRN
MAPT/TAU Microtubule associated protein tau Deletion of 29 amino acids with
reference to var 1 (insertion
with reference to var 2)
BRN
MEF2B MADS box transcription enhancer factor 2 N/A Not detected (LNG, TST, PLC)
NFKBIB/IKBb I-kappa-B-beta Deletion of 85 amino acids from
the N-terminus
BRN
NOS2A
§ Nitric oxide synthase 2A Deletion of 65 amino acids TST
PCBP2
§ Heterogeneous nuclear ribonucleoprotein
E2/ poly(rC) binding protein 2
Deletion of 31 amino acids BMR, BRN, BRST, PLC
PDHA Pyruvate dehydrogenase complex, E1-alpha
polypeptide 1 precursor
Insertion of 38 amino acids LNG, BRN
PPT1 Palmitoyl-protein thioesterase 1 N/A Not detected (BRST, LNG)
PRP18 Pre-mRNA processing factor 18 Insertion of nine amino acids SkM
RPN2 Ribophorin II N/A Not detected (TST)
SCAMP2 Secretory carrier membrane protein 2 N/A Not detected (BRN)
SCML1
§ Sex comb on midleg-like 1 Insertion of 28 amino acids TST
SH3BGR SH3-binding domain and glutamic acid-rich protein N/A Not detected (LNG and TST)
SLC3A2 Solute carrier family 3, member 2 N/A Not detected (BRN, SPL and PLC)
SUPT5H Suppressor of TY 5, Saccharomyces cerevesiae, homolog of Deletion of four amino acids BRN
¼
SRRM1/SRM160
§ Serine/arginine repetitive matrix protein 1 Insertion of 14 amino acids LNG, SPL and PLC
TAF2 TATA box-binding protein-associated factor, 2B N/A Not detected (BMR, BRN and SPL)
TEX27/Hs.6120 Testis expressed gene, 27 Deletion of 33 amino acids BRN
TIE1 Tyrosine kinase with immunoglobulin and EGF factor
homology domains
Deletion of 43 amino acids LNG and BRN
TIM17b Translocase of inner mitochondrial membrane 17 N/A Not detected (BRN and LNG)
TPD52L2
§ Tumor protein D52-like 2 (D54) Insertion of 23 amino acids BRN
UBE1C Ubiquitin-activating enzyme E1C Deletion of 27 amino acids Not detected (PLC and SPL)
WARS Trytophanyl-tRNA synthetase Truncation of the C-terminus TST and LNG
WBP2 WW domain-binding protein 2 Deletion of 45 amino acids BRN and TST
Z391G Immunoglobulin superfamily protein Z391G Deletion of 94 amino acids LNG and PLC
TBC1D7 TBC1 domain family, member 7 Deletion of 27 amino acids BM, BRST and LNG
We validated novel splice forms using RT–PCR, in one or more of the following tissues: BMR-bone marrow; BRN-brain; LNG-lung; KDN-kidney; SPL-spleen;
SKM-skeletalmuscle;TST-testis;PLC-placenta;BRST-breast.Toindicatetherelativeabundanceofthenovelspliceformineachtissue,wewritethetissue’snamein
boldfaceifthenovelformwasmoreabundantthantheknownform;inplainfontiftheknownformwasmoreabundantthanthenovelform;initalicsifonlythenovel
form(andnottheknownform)wasobserved;
¼denotesthatboththeknownandthenovelformswereequallyabundant.
§indicatesthatthesegeneswereselectedfor
further expression analysis (see Supplementary Data).
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ented by an mRNA sequence in the February 2005 data.
Screening of a panel of normal tissues and
tumor-derived cell lines
To assess the expressionpatterns ofnovel normalsplice forms,
we selected a random sample of 10 genes and screened each in
a panel of 8 normal tissues (bone marrow, brain, breast, lung,
skeletal muscle, placenta, spleen and testes), and 5 cell lines
derived from glioblastomas and neuroblastomas. In 4 of the
10 genes the novel splice form was the dominant isoform in
most normal tissues, or had approximately equal representa-
tion in normal tissues to that of the known splice form (see
Supplementary Data). In two other genes, the novel splice
form was strongly restricted to speciﬁc tissues, and in three
other genes, the novel splice form was ubiquitously expressed,
but at a much lower level than the known splice form
(Supplementary Data).
In two genes (BCAS1 and CHFR), the novel splice form
appeared to be lost in glioblastoma and neuroblastoma
cell lines (Figure 1). BCAS1 (Breast carcinoma ampliﬁed
sequence 1) was originally cloned from breast carcinomas
and is overexpressed in breast cancers (27). Though little is
known about its function, BCAS1 is a candidate oncogene.
BCAS1 was expressed only as the novel splice form in
brain, but only the known splice form was detected in the
braintumor-derived celllines. InCHFR,thepicturewassome-
what more complex. The novel splice form was expressed at
a low level in most normal tissues, but was apparently absent
from all the tumor cell lines tested. CHFR encodes a protein
with forkhead-associated and RING ﬁnger domains and
deﬁnes a checkpoint that delays entry into metaphase (28).
Methylation-dependent silencing of CHFR is seen in many
tumors (29). EST-genomic alignments indicated that the
known form is observed in both tumor and normal tissues
(four ESTs from tumors and three ESTs from normal tissues),
whereas anovel spliceform isobservedintwo ESTsbothfrom
normal testis. Our RT–PCR results showed the novel splice
form to be the dominant form in testis (in agreement with the
EST results), and to be present in most normal tissues (includ-
ing brain), but usually at a lower level than the known form.
In contrast, the novel splice form was missing from the ﬁve
tumor cell lines. Sequencing of the band corresponding to the
novel splice form matched the novel splice form sequence
predicted by the ESTs and results in an exon skip removing
92 amino acids (Table 1). However, CHFR displays additional
alternative splice forms and requires further study.
Figure1.Screeningofapanelofnormaltissuesandtumor-derivedcelllinesusingRT–PCR.RT–PCRwasperformedoncDNAsfromnormal,non-canceroustissues
(lettered in black) and from tumor-derived cell lines (lettered in red). 2% agarose gels were run, and bands visualized by ethidium bromide staining. N denotes the
band corresponding to the novel splice form, and K denotes the band corresponding to the known splice form. The genes shown are BCAS1 (upper gel) and CHFR
(lower gel).
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splice form of IKBb
As an example of our results that illustrates their potential
interest to cancer researchers, we have identiﬁed a novel splice
variant of IKBb (NFKBIB), a key regulator of NFkB activa-
tion (Supplementary Data). The complete mRNA sequence for
IKBb that is deposited in GenBank is from a pancreas epi-
thelioid carcinoma library [MGC 70; (30)]. A total of 17 ESTs
(primarily from tumors or tumor cell lines) support this
mRNA. However, three ESTs from a normal brain library
(MGC 119) support a novel alternative splice variant. We
validated this novel splice variant from normal brain cDNA
by both RT–PCR and sequencing (Supplementary Data). This
alternative splice variant (Supplementary Figure 2A) replaces
the ﬁrst exon with a shorter exon, resulting in a truncation of
the N-terminus, removing 86 amino acids (Supplementary
Data). The region removed by the novel splice encodes
important functional motifs, including two phosphorylation
sites and the ﬁrst ankyrin domain. In an inactive state,
NFkB exists as homo- or heterodimers associated with IKB
proteins (both IKBa and IKBb). An inducing signal results in
the phosphorylation, polyubiquitination and subsequent
degradation of IKB, leading to dissociation of NFkB, local-
ization tothe nucleusand activation [reviewed in(31,32)].The
shorter splice form of IKBb lacks the phosphorylation sites
at S19 and S23, and this seems very likely to affect NFkB
signaling. Experimental studies of its impact on NFkB func-
tion and regulation may require development of new IKBb
antibodies, since most existing anti-IKBb antibodies were
raised using N-terminal peptide fragments and may not be
able to detect the novel isoform.
DISCUSSION
Our experimental data clearly show that the novel normal
splice forms predicted by our previous bioinformatics work
are a real feature of normal human tissues. Even examining
only a small sample of human tissues (typically only 1–3
different tissues), we were able to ﬁnd  60% of the novel
normal splice forms predicted by bioinformatics, and sequen-
cing of these forms exactly matched the form predicted by
bioinformatics in every case tested. It should be emphasized
that our study focused on in-frame exon skips (i.e. alternative
splicing events that add or remove an exact multiple of 3 nt,
leaving the protein reading frame unchanged), to avoid
including alternative splice forms that might cause nonsense-
mediated decay (24). Thus, the absence of database records
for the novel normal splice forms cannot be attributed to
nonsense-mediated decay of ‘aberrant’ splice forms that do
not give rise to a protein product. Our analysis of GenBank
(both from 2002 data and 2005 data) shows both that public
databases lack many alternative splice forms, and intriguingly,
that this effect is much more pronounced for splice forms that
are associated with normal tissues, than for the splice forms
associated with tumors. At least for the set of  300 genes in
this study, the tumor-associated splice forms appear to be
‘over-represented’ relative to the normal-tissue-associated
splice forms. This highlights both a problem and an oppor-
tunity for cancer researchers.
Our results suggest several reasons why normal splice forms
for many cancer genes may have been missed. Many such
genes were originally cloned from tumor samples, introducing
a potential bias for tumor-speciﬁc splice forms instead of the
normal splice form. This bias could be particularly strong for
genes such as CHFR and BCAS1, where the novel splice form
appears to be lost in tumor cell lines. Indeed, when we
scrutinized the tissue origins of the mRNAs for the genes
in this study, we found that 70% were cloned from tumor
samples (Supplementary Data). Thus, it is not surprising
that the tumor splice form is known, and that many normal
splice forms have been missed. In about half of the genes we
have studied, the novel splice form was restricted to certain
tissues or expressed at a much lower level than the known
splice form. For such genes, detecting the novel splice form
probably would have required sequencing multiple cDNAs
from different normal tissue samples. Unfortunately, it has
been common practice, even inmanysophisticated sequencing
projects (e.g. the Mammalian Gene Collection), to halt further
sequencing ofa gene once asingle full-length mRNA isdepos-
ited. It should also be noted that these alternative splice forms
often produce protein variants whose molecular weight is very
similar to the known form, differing by only a few kilodaltons,
and thus may be hard to distinguish by electrophoresis and
related methods.
Our database of novel normal splice forms can be of value
for cancer researchers for several reasons. First, the sequence
of such a splice form may immediately suggest important
implications for the function or regulation of a gene involved
in cancer. For example, in the case of IKBb, the novel normal
splice form that we identiﬁed removes phosphorylation sites
that are important for regulation of the protein’s stability,
and thus its regulation of NFkB signaling (see Results and
Supplementary Data). Such implications deserve further
experimental study, and could lead to new insights into the
gene’s function (and thus regulation of the NFkB pathway) in
normal tissue. Predicted functional effects for some of our
novel splice variants are shown in Table 2. Second, our
data show that public databases are far from complete in
their cataloging of alternative splice forms, even for well-
studied genes. About 60% of the splice forms detected by
both our bioinformatics and experimental analyses are not
represented in GenBank. In a recent experimental study of
162 well-studied genes that are the targets of existing drug
therapies, Jin et al. (10) identiﬁed novel splice forms (not
reported in GenBank or RefSeq) in 70% of the genes by per-
forming RT–PCR on a pooled panel of human tissue samples.
Thus, even for genes that have been intensively studied
because of their role in human disease processes, the existence
of novel splice forms is the rule, not the exception. Third, our
data indicate that in a large fraction of cases (30–40%), the
novel normal splice forms in our database actually constitute
the dominant splice form in normal tissues (see Results and
Supplementary Data). Thus, the absence of these splice forms
from public databases means that researchers are not just
missing a splice form, but are actually missing the main splice
form of the gene. Fourth, the GenBank sequence for a given
gene may actually reﬂect a tumor splice form. While this is a
valid concern for any gene, it is of particular concern for genes
involved in cancer, since many such genes were originally
cloned and sequenced from tumor libraries.
Nucleic Acids Research, 2005, Vol. 33, No. 16 5031Discovery of the normal tissue forms of these genes, as
provided by our data, and comparison with their tumor
forms, could shed a useful new light on the action of many
cancer genes. Our novel-normal database currently contains
1308 novel normal splice forms for 804 human genes, includ-
ing exon skip events, alternative 50 and alternative 30 splicing,
and alternative initiation and alternative termination. This
database, available at http://www.bioinformatics.ucla.edu/
ASAP (33), can provide cancer researchers with a shortcut
for identifying whether there are novel normal splice forms for
their gene of interest, and whether these forms reveal likely
functional changes in their sequences. Our database also tabu-
lates evidence for tumor-speciﬁc shifts in alternative splicing,
when a splice form is observed much more frequently in
tumors than in normal tissue samples (14).
We wish to emphasize that care is required in interpreting
comparisons between splice forms observed in normal versus
tumor samples. First, such differences need not be absolutely
black and white. While in some cases we have observed a
strong switch from one splice form (S) in normal tissues to a
different splice form (S0) in tumors, other mechanisms are also
common, such as gain of S0 (in which the S0 form, rare in
normal tissue, becomes common in tumors, while the S
form remains constant), and loss of S (in which the S form,
common in normal tissue, becomes signiﬁcantly depressed in
tumors,while the S0 formremains constant) (14). Thus, there is
no contradiction in noting that the normal tissue splice form
(S) may also be observed in tumors; this is what is expected
under the gain of S0 mechanism. Second, tumors are highly
heterogeneous, so one cannot conclude that a splice form is
‘cancer-speciﬁc’ from examination of just a few samples. To
address this more challenging question, would require a large
panel of tumor samples, each with a tissue-matched normal
control sample. Moreover, since the results would likely vary
signiﬁcantly from tumor to tumor (due to tumor heterogen-
eity), careful statistical analysis would be required to demon-
strate a signiﬁcant association with a speciﬁc splice form. In
this paper, we have deliberately not addressed this challenging
question, since in our view it is ﬁrst necessary to prove the
existence of our putative ‘novel normal’ forms in normal tis-
sues, before attempting to show that these genes shift to a
different splice form in tumors. However, our current results,
combined with our ‘novel normal’ isoforms database, should
make it possible for many researchers to begin the studies
necessary for assessing whether these genes indeed show
cancer-speciﬁc changes in splicing in different tumor types.
SUPPLEMENTARY DATA
Supplementary Data is available at NAR Online.
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